**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 63837

**Manuscript Type:** EDITORIAL

**Transition of an acronym from nonalcoholic fatty liver disease to** **metabolic dysfunction-associated fatty liver disease**

Alam S *et al*. Transition from NAFLD to MAFLD

Shahinul Alam, Shah Mohammad Fahim

**Shahinul Alam,** Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka 1000, Bangladesh

**Shah Mohammad Fahim,** Nutrition and Clinical Services Division, ICDDR, Dhaka 1212, Bangladesh

**Author contributions:** Alam S and Fahim SM contributed to this paper; Alam S designed the overall concept and outline of the manuscript; Fahim SM contributed to the discussion and design of the manuscript; Alam S and Fahim SM contributed to the writing, and editing the manuscript, and review of literature.

**Corresponding author: Shahinul Alam, FCPS, MBBS, MD, Doctor, Professor,** Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka 1000, Bangladesh. shahinul@bsmmu.edu.bd

**Received:** February 4, 2021

**Revised:** May 10, 2021

**Accepted:** August 12, 2021

**Published online:**

**Abstract**

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern owing to its substantial contribution to chronic liver diseases. The disease is closely linked to metabolic syndrome (MS), suggesting a common biological pathway and shared disease mechanism for both ailments. Previous studies revealed a close relationship of NAFLD with the components of MS including abdominal obesity, dyslipidemia, hypertension, and hyperglycemia. Hence, a group of experts recently renamed NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD) in order to encompass a more appropriate pathogenesis of the disease. NAFLD was first named to describe a condition similar to alcoholic hepatitis in absence of significant alcohol consumption. However, knowledge pertaining to the etiopathogenesis of the disease has evolved over the past four decades. Recent evidence endorses NAFLD as a terminology of exclusion and suggests that it may often leads to misdiagnosis or inappropriate management of patients, particularly in clinical practice. On the other hand, the new definition is useful in addressing hepatic steatosis with metabolic dysfunction, which ultimately covers most of the patients with such illness. Therefore, it seems to be helpful in improving clinical diagnosis and managing high-risk patients with fatty liver disease. However, it is imperative to validate the new terminology at the population level to ensure a holistic approach to reduce the global burden of this heterogeneous disease condition.

**Key Words:** Nonalcoholic fatty liver disease; Metabolic dysfunction-associated fatty liver disease; Redefining; Redefinition of fatty liver disease

Alam S, Fahim SM. Transition of acronym from nonalcoholic fatty liver disease to metabolic (dysfunction) associated fatty liver disease. *World J Hepatol* 2021; In press

**Core Tip:** A consensus of experts recently renamed nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. The new definition is advantageous for improving clinical diagnosis and managing high-risk patients with fatty changes in liver.

**INTRODUCTION**

The rising burden of nonalcoholic fatty liver disease (NAFLD) is a global public health concern. This progressive liver disease is a leading cause of chronic hepatic ailments worldwide[[1](#_ENREF_1),[2](#_ENREF_2)]. Recent reports confirm that NAFLD accounts for approximately 8% of the annual 2.14 million global deaths from liver disease[[3](#_ENREF_3)]. Over the past two decades a substantial elevation in the prevalence of NAFLD has been reported, with strong evidence of a close link between NAFLD and metabolic syndrome (MS)[[4](#_ENREF_4)]. NAFLD is often found to be associated with the components of MS, such as abdominal obesity, dyslipidemia, hypertension, and hyperglycemia[[5](#_ENREF_5)]. In addition, the risk factors of NAFLD and MS have also been found to be identical in many studies[[1](#_ENREF_1)]. Therefore, it has been suggested that both NAFLD and MS follow a common biological pathway as well as a shared disease mechanism. In line with that, a consensus of experts recently renamed NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) so that the term could accurately reflect the pathogenesis of the disease[[6](#_ENREF_6)]. According to the new definition, MAFLD would be diagnosed if there was evidence of hepatic steatosis in addition to any of the following three conditions, overweight/obesity, type 2 diabetes mellitus, or metabolic dysregulation[[7](#_ENREF_7)]. The expert opinion was that the new definition is superior for diagnosing NAFLD patients with severe liver injury. Moreover, it is more practical to diagnose high-risk patients and evaluate disease progression in clinical settings[[8](#_ENREF_8),[9](#_ENREF_9)].

**Discussion**

Nonalcoholic steatohepatitis (NASH) was first used nearly four decades ago to describe a condition that mimics alcoholic hepatitis in absence of significant alcohol consumption[[10](#_ENREF_10)]. Initially, the pathology was found to be linked to obesity or obesity-associated disorders. Subsequently, the disease was renamed NAFLD, referring to the absence of any known etiology of liver disease. In the meantime, a detailed understanding of the etiopathogenesis of the disease has evolved as the link between NAFLD, insulin resistance, and other components of MS was explored. Molecular-level investigations explored the role of multiple genetic and cellular mechanisms in the pathogenesis of NAFLD[[11](#_ENREF_11)]. Epidemiological studies also revealed a number of social, demographic, and clinical determinants responsible for development of NAFLD[[12](#_ENREF_12)]. Results of the studies described NAFLD as a heterogeneous condition. However, the archaic NAFLD nomenclature, which is a terminology of exclusion, remained unchanged over the years. The inclusion of alcohol in the name and definition is also problematic. In real-life clinical practice, the features of NAFLD often overlap with the characteristics of patients who consume alcohol. Moreover, there is no accepted method to appropriately measure alcohol intake in clinical facilities. Hence, there remains a possibility of misdiagnosis or inappropriate management of patients. Considering the above context, there has been a proposal to change the name since the beginning of this century. As the disease was found to be closely associated with metabolic dysfunction and insulin resistance, the scientific community proposed several names related to metabolic dysfunction, for example, metabolic steatohepatitis, metabolic fatty liver disease, and metabolic-associated fatty liver[[10](#_ENREF_10)]. Eventually, a consensus of global experts opted for MAFLD.

It is assumed that the new definition would improve clinical diagnosis (Table 1). The term MAFLD annulled two different NAFLD entities, simple steatosis and NASH, and conceptualized the fatty changes in the liver as a disease process. Therefore, the redefinition of MAFLD would help to overcome the dichotomization of NASH and non-NASH, and facilitate the assessment of disease severity in clinical practice[[13](#_ENREF_13)]. A recent study reported that the switch from NAFLD to MAFLD increased the awareness of physicians regarding the management of the disease[[14](#_ENREF_14)]. However, changes in nomenclature may have potential implications for ongoing clinical trials in which “improvement in NASH” is an outcome variable. It is possible to redefine the outcomes of clinical trials based on the existing MAFLD framework, but there remains certain disagreement regarding the new terminology and its definition that need to be addressed[[15](#_ENREF_15)]. The new criteria may underestimate the actual prevalence of the disease, as reported in a recent study[[8](#_ENREF_8)]. It may also exclude patients without metabolic disturbances. A recent review found that metabolic derangements may be absent in 30% of the patients diagnosed with NAFLD[[5](#_ENREF_5)]. The new definition is also not clear regarding concomitant liver diseases such as drug-induced, viral or auto-immune liver disease. Apart from individuals with high body mass index, NAFLD has also been reported in lean and nonobese adults. It is assumed that visceral adiposity and differences of metabolic adaptations may play a potential role in the pathogenesis of hepatic steatosis in lean adults[[16](#_ENREF_16)]. Alterations in gut microbiota can also be a contributing factor in developing NAFLD in lean and undernourished adults[[16](#_ENREF_16)]. Moreover, there is evidence in support of a significant relationship between a positive family history of metabolic traits and NAFLD, particularly in lean patients with a fatty liver[[17](#_ENREF_17)]. Individuals with a family history of metabolic traits are likely to develop complications of NAFLD at a younger age[[18](#_ENREF_18)]. Therefore, body fat content, rate of weight gain, and family history of metabolic traits need to be considered when constructing a new conceptual framework to define MAFLD. It seems that diagnosis of cryptogenic cirrhosis attributable to metabolic derangements would be easier using the new definition of MAFLD, as cryptogenic cirrhosis was found to be associated with obesity and diabetes[[19](#_ENREF_19)]. Nevertheless, a more insightful opinion is required to establish an accurate definition so that the term incorporates individuals with hepatic fatty changes in the absence of metabolic derangements. Moreover, there should be definitive guidelines regarding inclusion of genetic risk factors, phenotypic measurements, dietary intake, visceral adiposity, and alterations in gut microbiota in the definition.

**CONCLUSION**

As more than one-fourth of the global population have NAFLD. Emphasis should be given to appropriate understanding of etiopathogenesis of the ailment[[20](#_ENREF_20)]. To that end, an appropriate term is required so that it can reflect the entire pathophysiology of the disease and cover the whole population with perturbed accumulation of hepatic fat. The new definition seems to address hepatic steatosis with metabolic dysfunction, which ultimately covers most of the cases with such illness. It is also useful for improving clinical diagnosis and managing high-risk patients with fatty changes in the liver. Therefore, the shift in terminology from NAFLD to MAFLD has already attained global endorsement. However, validation of the new term at the population level is warranted to ensure a holistic approach to reduce the global burden.

**REFERENCES**

1 **Bellentani S**. The epidemiology of non-alcoholic fatty liver disease. *Liver Int* 2017; **37**: 81-84 [PMID: 28052624 DOI: 10.1111/liv.13299]

2 **Golabi P**, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). *Medicine (Baltimore)* 2018; **97**: e0214 [PMID: 29595666 DOI: 10.1097/MD.0000000000010214]

3 **Paik JM**, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. *Hepatology* 2020; **72**: 1605-1616 [PMID: 32043613 DOI: 10.1002/hep.31173]

4 **Kumar R**, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. *J Clin Transl Hepatol* 2020; **8**: 76-86 [PMID: 32274348 DOI: 10.14218/JCTH.2019.00051]

5 **Kim D**, Touros A, Kim WR. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. *Clin Liver Dis* 2018; **22**: 133-140 [PMID: 29128053 DOI: 10.1016/j.cld.2017.08.010]

6 **Eslam M**, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology* 2020; **158**: 1999-2014.e1 [PMID: 32044314 DOI: 10.1053/j.gastro.2019.11.312]

7 **Eslam M**, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020; **73**: 202-209 [PMID: 32278004 DOI: 10.1016/j.jhep.2020.03.039]

8 **Lin S**, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. *Liver Int* 2020; **40**: 2082-2089 [PMID: 32478487 DOI: 10.1111/liv.14548]

9 **Niriella MA**, Ediriweera DS, Kasturiratne A, De Silva ST, Dassanayaka AS, De Silva AP, Kato N, Pathmeswaran A, Wickramasinghe AR, de Silva HJ. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. *PLoS One* 2021; **16**: e0245762 [PMID: 33534815 DOI: 10.1371/journal.pone.0245762]

10 **Fouad Y**, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'. *Liver Int* 2020; **40**: 1254-1261 [PMID: 32301554 DOI: 10.1111/liv.14478]

11 **Kuchay MS**, Misra A. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years. *Diabetes Metab Syndr* 2020; **14**: 695-696 [PMID: 32442920 DOI: 10.1016/j.dsx.2020.05.019]

12 **Perumpail BJ**, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. *World J Gastroenterol* 2017; **23**: 8263-8276 [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263]

13 **Yilmaz Y**, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. *Expert Rev Gastroenterol Hepatol* 2021; **15**: 345-352 [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019]

14 **Fouad Y**, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. *J Hepatol* 2021; **74**: 1254-1256 [PMID: 33582129 DOI: 10.1016/j.jhep.2020.12.035]

15 **Younossi ZM**, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, Cohen DE, Loomba R. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. *Hepatology* 2021; **73**: 1194-1198 [PMID: 32544255 DOI: 10.1002/hep.31420]

16 **Chen F**, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. *Hepatology* 2020; **71**: 1213-1227 [PMID: 31442319 DOI: 10.1002/hep.30908]

17 **Fahim SM**, Chowdhury MAB, Alam S. Non-alcoholic fatty liver disease (NAFLD) among underweight adults. *Clin Nutr ESPEN* 2020; **38**: 80-85 [PMID: 32690182 DOI: 10.1016/j.clnesp.2020.06.002]

18 **Bhadoria AS**, Kedarisetty CK, Bihari C, Kumar G, Jindal A, Bhardwaj A, Shasthry V, Vyas T, Benjamin J, Sharma S, Sharma MK, Sarin SK. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: A cross-sectional study. *Liver Int* 2017; **37**: 1397-1404 [PMID: 28231412 DOI: 10.1111/liv.13396]

19 **Caldwell SH**, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. *Hepatology* 1999; **29**: 664-669 [PMID: 10051466 DOI: 10.1002/hep.510290347]

20 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 4, 2021

**First decision:** May 3, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Bangladesh

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Zheng SM **S-Editor:** Wu YXJ **L-Editor:** Filipodia **P-Editor:**

**Table 1 Potential positive implications and challenges related to transition of nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease**

|  |  |
| --- | --- |
| **Positive implications** | **Challenges** |
| Useful in overcoming the dichotomization of NASH and non-NASH in clinical practices | Obtain a global acceptance as some researchers consider the name change premature and inappropriate |
| Facilitate diagnosis and evaluation of disease progression in high-risk patients | Underestimation of actual prevalence of the disease using the criteria of MAFLD |
| Improve awareness of physicians, healthcare providers and patients | Further clarification and stratification of the definition to guide decision-making and assess prognosis of the disease |
| Improve physician-patient communication | Address the patients with fatty changes in liver in absence of metabolic derangements |
| Improve clinical diagnosis and patient care | Deal with lean or undernourished individuals with hepatic fatty changes |
| Reduce confusion and stigma regarding the disease | Lack of information regarding genetic risk factors, phenotyping measurements, body fat content, and alterations in gut microbiota in the new definition |
| Increase public attention and improve health policy actions | Determine the outcome variable of ongoing clinical trials where “improvement in NASH” is one of the endpoints |

MAFLD: Metabolic dysfunction-associated fatty liver disease; NASH: Nonalcoholic steatohepatitis.